MEDP
NASDAQ · Life Sciences Tools & Services
Medpace Holdings Inc
$624.20
+11.87 (+1.94%)
Financial Highlights (FY 2026)
Revenue
2.40B
Net Income
428.43M
Gross Margin
30.1%
Profit Margin
17.8%
Rev Growth
+20.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 30.1% | 30.1% | 65.6% | 65.6% |
| Operating Margin | 21.1% | 19.0% | 22.1% | 20.6% |
| Profit Margin | 17.8% | 16.9% | 15.7% | 13.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.40B | 2.00B | 3.49B | 4.35B |
| Gross Profit | 722.32M | 601.34M | 2.29B | 2.85B |
| Operating Income | 507.98M | 380.61M | 769.54M | 895.01M |
| Net Income | 428.43M | 321.00M | 546.82M | 598.50M |
| Gross Margin | 30.1% | 30.1% | 65.6% | 65.6% |
| Operating Margin | 21.1% | 19.0% | 22.1% | 20.6% |
| Profit Margin | 17.8% | 16.9% | 15.7% | 13.8% |
| Rev Growth | +20.1% | +20.1% | +10.1% | +3.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 4.34B | 5.18B |
| Total Equity | — | — | 10.33B | 11.31B |
| D/E Ratio | — | — | 0.42 | 0.46 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 534.73M | 422.91M | 1.04B | 1.45B |
| Free Cash Flow | — | — | 536.95M | 745.18M |